Ozempic Lawsuit: Lawsuits Filed Against Ozempic (December 2024)

Legally Reviewed

This article has been written and reviewed for legal accuracy and clarity by Lawsuit Legal News' writers and attorneys and is accurate as possible. This content should not be taken as legal advice from attorney.

Fact-Checked

Lawsuit Legal News does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us. This article should not be taken as advice from an attorney.

The Ozempic Lawsuit is an ACTIVE Lawsuit

Click Here to View the Latest Updates

Numerous Ozempic lawsuits have been filed by patients who suffered severe and harmful symptoms. This past spring, the ailment affecting most plaintiffs was gastroparesis, a paralysis of the stomach. However, in recent months, we have begun investigating claims of vision loss and blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism, following the use of Ozempic or Wegovy.

In early July, a new study linked prolonged Ozempic use to a condition known as NAION. NAION is the second leading cause of adult blindness. We expect more studies to be published over the next year. 

We are seeing more adverse event reports filed with the FDA by individuals who sustained a blood clot following the use of Ozempic or Wegovy. This adds validity to a 2022 study published in the Endocrine Journal that demonstrated a 266% increased risk of deep vein thrombosis (DVT) for individuals who used Ozempic. 

Every lawsuit is filed against its manufacturer, Novo Nordisk. We are now also seeing several lawsuits filed against Mounjaro's manufacturer, Eli Lilly, and Co. All federal Mounjaro or Ozempic lawsuits have been consolidated before Judge Pratter in the Eastern District of Pennsylvania. 

Both drugs are regularly being used off-label for weight loss or as weight loss medications; the diabetes drugs Ozempic and Mounjaro were initially manufactured for diabetes therapy.

Ozempic Litigation - The Ozempic Class Action Lawsuit

Each lawsuit claims the blockbuster drugs are to blame for the plaintiff's severe gastroparesis. These lawsuits are part of the coordinated litigation against Novo Nordisk (Ozempic) and Eli Lilly (Mounjaro), which are already facing litigation regarding gallstone risk. It turns out the miracle weight loss drug is allegedly far more dangerous than the general public is aware of.

Many plaintiffs were using Ozempic or similar drugs to treat obesity and lose a significant amount of weight—as so many people in America have done. But, there was a darker outcome that they had no idea was coming. Ozempic, Wegovy, and similar drugs have been proven to cause severe gastrointestinal and gallbladder problems.

Ozempic Lawsuit Filed Over Vision Loss (NAION) & Blood Clot

Further, credible published studies link Ozempic to NAION (non-arteritic anterior ischemic optic neuropathy). Research has also recently discovered a possible increased risk of vision loss for Ozempic users.

The team at Lawsuit Legal News is investigating the link between semaglutide drugs like Ozempic and a severe eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION. If you have experienced vision loss after using Ozempic or another similar drug, contact the LLN team to learn more about a potential Ozempic vision loss lawsuit. NAION is the second most common form of optic nerve disease and can result in irreversible blindness. 

We are also seeing a growing number of individuals presenting to emergency rooms with complaints of a blood clot following the use of Ozempic. A 2022 study found that individuals using semaglutide (Ozempic or Wegovy) have a 266% increased risk of deep vein thrombosis. If Ozempic or another similar drug has harmed you, contact the LLN team to learn more about a potential Ozempic vision loss lawsuit.

A medication created to treat diabetes has exploded in popularity. In the past year, however, the filing of Ozempic lawsuits began in Federal District Courts nationwide. In April 2024, the Judicial Panel on Multidistrict Litigation consolidated all lawsuits before one Judge in the United States District Court for the Eastern District of Pennsylvania. 

We expect to see significant movement in the Ozempic lawsuit as 2024 approaches. We anticipate seeing more developments in linking Ozempic exposure to gastrointestinal issues (gastroparesis, ileus, etc.), pancreatitis, and other medical conditions, including NAION (vision loss) and gallbladder problems.

<iframe width="200" height="113" src="https://www.youtube.com/embed/vafnRCCktuE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen title="From the Ozempic Lawsuit to the Paragard Lawsuit: Fighting for Justice"></iframe>

If you or someone you love has suffered stomach, intestinal, or gallbladder problems after using Ozempic, reach out to protect your legal rights today. Call us at 866-535-9515 or complete our simple online form to schedule a free consultation.

Contact the dedicated legal team at Lawsuit Legal News.

Contact the dedicated legal team at Lawsuit Legal News

Table Of Contents

Keep in mind that this prescription drug has caused enough severe problems that the FDA required new medication labels to warn about the risk of intestinal blockage. For these reasons alone, we believe Ozempic, Wegovy, and Mounjaro are poor choices for long-term weight management.

The damages resulting from these unmentioned and dangerous side effects caused by Ozempic are potentially compensable, meaning a person can recover money for their medical bills, lost wages, pain and suffering, inconvenience, and future medical bills.

To do this, anyone injured by a GLP-1 medication needs to file a lawsuit with the assistance of a reputable product liability lawyer—ideally, one who has handled thousands of lawsuits against defective drug makers, medical device manufacturers, toxic chemical producers, and other harmful products.

Since Novo Nordisk placed a warning on their Ozempic labels, the time to bring a claim may be running out. Keep in mind the warning label only references intestinal blockage and gallbladder issues.

Our experienced mass tort drug attorneys can explain more about the money you may receive if Ozempic has injured you. Call us at 866-535-9515 or complete our simple online form to schedule a free consultation and case review today.

Talk to a Dangerous Drug attorney now.

Talk to a Dangerous Drug attorney now

The First Gastroparesis Ozempic Lawsuit

The new Ozempic lawsuit against Novo Nordisk and Eli Lilly regarding their diabetes drugs, Ozempic and Mounjaro, involves a 44-year-old woman from Louisiana who took both diabetes drugs and consequently developed severe symptoms associated with gastroparesis. The plaintiff is reported to have suffered severe gastroparesis symptoms, such as vomiting with sufficient intensity to cause the loss of teeth.

The Ozempic and Mounjaro stomach paralysis lawsuit was announced Wednesday, August 2, 2023, and has been filed based on “failure to warn” regarding Eli Lilly and Co. and Novo Nordisk's lack of appropriate labeling informing consumers such as the plaintiff of risks such as gastroparesis. While many folks use both medications to control type one diabetes, many others use it off-label for the long term. 

What Is Gastroparesis?

Gastroparesis, or delayed gastric emptying, is a disorder of the digestive system where the muscles that move food along the digestive tract work slower and cause numerous negative symptoms. The muscles along the digestive tract use spontaneous movement to push food along in a process known as motility. When motility is disrupted through gastroparesis, people can experience the following symptoms.

  • Vomiting
  • Nausea
  • Abdominal bloating
  • Abdominal pain
  • A feeling of fullness after eating just a few bites
  • Vomiting undigested food eaten a few hours earlier
  • Acid reflux
  • Changes in blood sugar levels
  • Lack of appetite
  • Weight loss and malnutrition
abdominal pain

Lawsuit Update

We aim to provide the most up-to-date coverage of the many different stomach paralysis lawsuits currently going through the courts.

If you are looking to file a lawsuit, check this page often. We will keep it updated with all the latest Ozempic news.

Sadly, we are routinely getting reports of adverse events that are far more serious than mere stomach pain associated with the use of a weight loss drug like Ozempic. Many of our clients are presenting with vision loss and blood clots following prolonged use of Ozempic. 

For more information about filing a potential lawsuit, contact us today at 866-535-9515 or complete our simple online form to schedule a free consultation. The law firm associated with Lawsuit Legal News is at the forefront of Ozempic lawsuits in all 50 states, including those consolidated in the United States District Court for the Eastern District of Pennsylvania.

December 1, 2024 - Supplements Addressing Ozempic Side Effects Raise Concerns About Long-Term Risks

The introduction of supplements like Replenza, formulated to counteract the side effects of Ozempic and other GLP-1 medications, underscores the significant health concerns associated with these drugs. Conditions such as "Ozempic face," characterized by rapid loss of skin elasticity, gastrointestinal issues, and even personality changes, have led to the development of products to mitigate these adverse effects.

The availability of such supplements highlights the potential risks of using Ozempic, prompting questions about its safety and long-term implications. Individuals should consult healthcare professionals to fully understand these risks before initiating treatment.

November 1, 2024 – Latest Updates on MDL 3094 Involving GLP-1 Agonist Drugs

In a recent move, the Eastern District of Pennsylvania's federal court advanced MDL 3094, consolidating lawsuits for GLP-1 agonist medications such as Ozempic, Wegovy, and others. This MDL, now with over a thousand claims, addresses reports of serious gastrointestinal effects tied to these drugs, including gastroparesis (stomach paralysis), intestinal blockages, and persistent nausea and vomiting.

The Court’s latest decision emphasizes two areas of early discovery: (1) testing methods to confirm gastroparesis and (2) whether the drug warnings adequately inform users of these risks. Plaintiffs allege that, while these drugs are often used off-label for weight loss, they come with significant and lasting health risks that the drugmakers, Novo Nordisk and Eli Lilly, did not adequately disclose.

This rapidly growing MDL highlights the scale of adverse reactions being reported by patients. While additional discovery on marketing efforts remains paused, this initial phase will shape how future cases proceed. We’ll continue to monitor and update this information as the MDL progresses.

The U.S. District Court for the Eastern District of Pennsylvania issued a new case management order in the ongoing multidistrict litigation (MDL) involving GLP-1 receptor agonists like Ozempic, Wegovy, and Trulicity. This MDL consolidates lawsuits from plaintiffs alleging gastrointestinal injuries, such as gastroparesis, from the use of these drugs. With 842 cases already included and thousands more expected, the court focused on streamlining the discovery process to address three key "cross-cutting" issues.

The first issue centers on gastroparesis diagnostic testing. Defendants argue that a reliable diagnosis of gastroparesis should be based on objective tests like gastric emptying studies, which many plaintiffs lack. The court agreed that early motion practice on this matter is essential, as it could significantly reduce the number of claims if the court finds such tests necessary.

The second issue involves preemption and the adequacy of warning labels. Defendants claim that the FDA-approved labels for these drugs provided sufficient warnings about gastrointestinal risks, which could shield them from liability. Plaintiffs, however, argue that the labels failed to warn of more severe conditions like gastroparesis. The court has allowed early discovery to resolve whether the labels were legally adequate or if federal law preempts state law claims.

Lastly, the court deferred ruling on the third issue, general causation, pending further briefings. This will explore whether the GLP-1 drugs can cause the alleged gastrointestinal injuries in a broad, general sense or if such determinations should be made on a case-by-case basis. This order marks a significant step in moving the litigation forward by resolving pivotal questions early.

Researchers have reviewed data from the World Health Organization (WHO) and published a study in the JAMA Network related to the main ingredient in Ozempic, Semaglutide. The study showed an increase in suicidal ideation among patients who used semaglutide drugs, like Ozempic and Mounjaro, along with other medications, specifically antidepressants. This latest research supports our theory that we still don't know the full extent of the devastating side effects related to these drugs.

The next court appearance is September 23rd. We expect the court to entertain expanded discovery opportunities regarding the defendants' drug marketing. The plaintiffs' goal is to present evidence that drug makers are ignoring or glossing over the true risks patients are facing.

September 5, 2024 - Plaintiffs Fight for Discovery Regarding Important Evidence; MDL Lawsuits More Than Double in One Month

The maker of Ozempic and other defendants want the court to make quick decisions based on limited evidence to end this litigation early. We discussed the "cross-cutting legal issues" below, specifically whether a diagnostic test should be required to prove a link between these drugs and gastroparesis and whether federal law controls the drugs' warning labels. If the parties are only allowed limited discovery on these issues, the court could make harmful decisions based on insufficient information.

The plaintiffs argue that this evidence should be considered under the Bradford Hill criteria because it is crucial to this litigation. The Bradford Hill criteria help determine legal causal relationships between a suspected medical condition and certain factors like drug side effects. The court should follow these guidelines in this litigation to determine if Ozempic is the legal cause of the alleged side effects, including gastroparesis.

In the past month alone, the number of Ozempic lawsuits filed in this MDL has more than doubled to 869 claims.

September 1, 2024 - Court Prioritizes Key Issues in GLP-1 Drug Litigation, Diagnostic Testing, and Label Adequacy

In this Ozempic MDL, the court prioritizes key issues related to diagnostic testing and the adequacy of warning labels, which could significantly influence the direction and outcome of the consolidated cases. The most recent Case Management Order addresses three critical issues in the early stages of this MDL, referred to as "cross-cutting" issues, because they are relevant to many, if not all, cases in the litigation. These issues are:

Gastroparesis Diagnostic Testing

  • What It Is: Gastroparesis is when the stomach cannot properly empty food. Many plaintiffs allege they developed gastroparesis after using Ozempic or similar drugs.
  • Court's Ruling: The court has agreed to prioritize early discovery and motions on whether gastroparesis can be reliably diagnosed without objective testing, such as a gastric emptying study. This is important because if it cannot be reliably diagnosed, it could significantly limit the number of claims related to this condition.

Preemption and Adequacy of Warning Labels

  • What It Is: This issue deals with whether the claims against the drug manufacturers are preempted by federal law, specifically whether the warnings on the drug labels, approved by the FDA, are legally sufficient.
  • Court's Ruling: The court has also agreed to prioritize this issue, allowing for early discovery and motions to determine if the drug labels adequately warned about the risks of gastrointestinal problems like gastroparesis. The outcome could impact the viability of many claims in the MDL.

General Causation

  • What It Is: General causation refers to whether the drugs are capable of causing the alleged injuries, such as gastroparesis and other gastrointestinal issues.
  • Court's Ruling: The court has deferred ruling on this issue, pending further briefing on how to determine whether there is a causal link between the drugs and the injuries claimed by the plaintiffs. The court will decide later whether to address this issue early in the proceedings.

Next Steps:

The parties must meet and discuss timelines for discovery and motion deadlines related to the first two issues, and a comprehensive scheduling order will be issued.

What This Means:

The court's decision to prioritize these cross-cutting issues aims to streamline the litigation by addressing key legal questions that could impact many cases. Depending on the outcomes, many of the claims could be narrowed or even dismissed, particularly if the court finds that the drug labels were adequate or that certain conditions like gastroparesis cannot be reliably linked to the use of these drugs without objective testing.

August 24, 2024 - New Court Order Favorable to Defendants

Judge Karen Marston issued a new order that seems gift-wrapped for the defense. More specifically, the most recent order will allow early discovery into the reliability of diagnostic testing for gastroparesis and whether the FDA-approved warning label for Ozempic is adequate. 

If Judge Marston ultimately determines the warning label to be sufficient, federal law will preempt any state law failure to warn claims. Further, we will soon learn about the reliability of gastroparesis diagnoses. 

Keep in mind that a manufacturer remains responsible for its warning label at all times. Thus, Novo Nordisk is responsible for updating its label with any newly acquired information. This includes adverse event reports filed with the FDA by individuals diagnosed with gastroparesis, NAION, or blood clots following their use of Ozempic or Wegovy.

August 14, 2024 - New Discovery Order Issued

Judge Marston's latest order spells out how plaintiff leadership will share costs incurred in advancing the Ozempic lawsuit pending in Pennsylvania federal court in the Eastern District of Pennsylvania. The order also provides a protocol for common benefit assessments, the funding of expert retention, and the necessary work as we advance.

August 13, 2024 - What is Ricezempic? Does Ricezempic Work?

The so-called "Ricezempic" has become a viral TikTok trend that claims to offer a budget-friendly alternative to the weight-loss drug Ozempic by using a rice water concoction. The Ricezempic drink is claimed to be full of resistant starches (a type of carbohydrate that the body digests in the large intestine, feeding good gut bacteria and acting like insoluble fiber).

Because the body can't break down resistant starch, it has similar effects to dietary fiber that suppress appetite and helps you feel full for longer (similar to GLP-1 drugs like Ozempic and Wegovy), which is what proponents of this weight loss trend say that Ricezempic does.

While some users tout its benefits, experts caution that there's no scientific evidence supporting rice water's effectiveness for weight loss and that it could pose health risks.

According to a registered dietitian interviewed by Healthline, Ricezempic has several risks.

The first is consuming uncooked or raw food can always create the possibility of food-borne illnesses, even with rice.

Second, rice is one of the main sources of arsenic so consuming a large amount of rice-infused water for weeks or months can increase one's exposure and concentration of this toxic heavy metal.

Finally, the nutritionist mentioned that starving yourself while only drinking water, as the diet recommends, is never good. Raw rice water can also cause gas, bloating, and constipation, so there's that.

User @avonnasunshine shows how she makes the trending "weight loss drink," Ricezempic.

August 10, 2024 - Status Conference Results

If you are following this case closely, know that the results of Thursday's status conference have not yet been made public. We will let you know as soon as we know.

August 8, 2024 - Status Conference Scheduled for Today (Aug 8)

A status conference is being held today, August 8, 2024, in the Ozempic mass tort case, alleging the drug manufacturer failed to adequately warn patients and doctors about the drug's severe side effects. During this conference, several key topics will be discussed:

  • Update on Electronic Plaintiff Fact Sheets (e-PFS): Review the progress and current status of the electronic submission of Plaintiff Fact Sheets.
  • Discovery Process Developments: The judge will get an update on the ongoing developments in the discovery process, including any milestones reached and challenges encountered.
  • Status of Temporarily Stayed Cases: Talks will be held regarding cases that have been temporarily stayed, focusing on the next steps and when the issues will be handled.
  • Science Day Planning: Arrangements and logistics will be worked out for the upcoming Science Day, where the court will hear from expert witnesses about the science behind the plaintiffs' claims and the defense's rebuttal.

This conference will be a big step forward as it will clarify the current state of the proceedings and begin planning the next phases of the litigation.

August 1, 2024 - The Danish Economy Runs on Ozempic - Anniversary of the First Ozempic Lawsuit

Why does Novo Nordisk continue to make Ozempic if it harms people? In a word, money. Denmark's economy has become heavily dependent on the production of Ozempic, a diabetes drug by Novo Nordisk.

This has driven significant economic growth and raised concerns about overreliance on a single industry, even though the drug has caused problems for some people. Despite its financial benefits, Ozempic has faced numerous lawsuits due to side effects, highlighting the risks of this economic dependency.

August marks the anniversary of the first lawsuit against Ozempic, filed on August 2, 2023. As of now, at least 117 lawsuits have been filed against Novo Nordisk, the manufacturer of Ozempic, primarily due to severe gastrointestinal side effects such as gastroparesis and ileus.

This figure includes cases consolidated into multidistrict litigation (MDL) in the Eastern District of Pennsylvania, which could eventually involve up to 10,000 plaintiffs. The lawsuits allege that Novo Nordisk failed to adequately warn users about these severe risks.​

July 12, 2024 - Can Ozempic Cause Blindness? - Alarming New Study Could Impact The Lawsuit

Ozempic and NAION

A new study involving 1687 patients, published in JAMA Ophthalmology, indicates that individuals using semaglutide exhibited an increased risk for developing NAION (nonarteritic ischemic optic neuropathy). NAION generally results in optic nerve blindness and is the second leading cause after Glaucoma.

While Ozempic NAION cases are extremely rare, we follow this development closely. The link is alarming enough that we plan to represent individuals in an Ozempic NAION lawsuit. Sadly, vision loss is only the latest risk associated with taking Ozempic. Ozempic's warning label does not mention blindness, let alone gastroparesis. 

July 1, 2024 - Five new lawsuits were filed in the MDL last month, bringing the total to 106.

Today marks the addition of another claim to the Ozempic litigation pending in Federal court. This latest case involves a woman from Indiana who initiated Ozempic treatment in March 2022, following her doctor's advice for managing both her diabetes and weight. 

One year later, on July 1, 2023 - notably the final day before the statute of limitations expired - she found herself in the emergency room. Her symptoms included severe gastroparesis, severe constipation, rectal bleeding, and vomiting. Diagnostic imaging revealed a bowel obstruction, which was treated before she was discharged. 

The plaintiff continues to grapple with ongoing digestive issues. Central to her claim is the assertion that the Ozempic product information failed to adequately communicate the full spectrum of potential risks to either her or her healthcare provider, including the potential for severe gastroparesis. Consequently, she contends that her quality of life has been significantly compromised due to her use of the drug Ozempic."

June 10, 2024 - New Judge Appointed in Ozempic Lawsuit After Prior Judge's Death

Following Judge Pratter's untimely and sad passing, a new Judge has been appointed in the Ozempic MDL. Judge Karen Spencer Marston, a former federal prosecutor, has been appointed to oversee the Ozempic lawsuit MDL in the Eastern District of Pennsylvania. She will preside over her first hearing in the MDL today.

June 6, 2024 - Ozempic Multidistrict Litigation Stalled Due to MDL Judge's Death, 101 Lawsuits Currently Pending

Judge Gene E.K. Pratter, the federal judge assigned to the Ozempic MDL, has died. She was 75. The MDL panel must now vet and appoint a new judge to manage this litigation. Of course, the new judge will need some time to get current on this complicated litigation.

Twelve new cases joined the federal MDL in May. Our team at LLN certainly expected this litigation to grow more quickly, but many injured plaintiffs may be waiting on the sidelines to see what happens.

May 22, 2024 - Science Day Canceled in Ozempic Class Action Lawsuit

Science Day has been canceled in the Ozempic lawsuit following Judge Pratter's untimely death. Ozempic litigation is presently paused pending the appointment of a new Judge. Mitchell Goldberg, Chief Judge in the United States District Court for the Eastern District of Pennsylvania, issued an order today canceling this event.

May 19, 2024 - Judge Pratter, Federal Judge Overseeing The Lawsuit, Dies at age 75

We are very sad that Judge Gene Pratter died at age 75, as was announced today, following a distinguished legal career. She was presiding over all Ozempic lawsuits that had been consolidated in the Eastern District of Pennsylvania. We anticipate a new Judge will be appointed to oversee the Ozempic Class Action Lawsuit.

May 16, 2024 - Court Establishes a Science Day, Parties Report Progress on Creating a Plaintiff Fact Sheet

June 14th is slated as "Science Day," when both sides will present a preview of the medical issues and scientific evidence involved in this Ozempic side effects lawsuit MDL. This court date should be non-adversarial. However, attorneys will use every opportunity to sway the court's opinions as early as possible. The science will pertain to whether glucagondWe believe there will inevitably be close to 40,000 Ozempic cases in this MDL alleging severe and permanent injuries from this diabetic and weight loss medication.s like peptide 1 medications, can cause gastroparesis and other related gastrointestinal issues.

Also, both sides have been working on creating an agreed-upon Plaintiff Fact Sheet (PFS) that includes the information all plaintiffs in this MDL will need to provide. An outside company, Rubris, will be responsible for processing these PFSs and other electronic submissions.

May 1, 2024 - The Number of Ozempic Stomach Paralysis Lawsuits Continues to Rise

As April wound down, more lawsuits joined the nationwide Ozempic multi-district litigation (MDL), claiming Ozempic use has caused gastroparesis (stomach paralysis), bowel obstructions, and ileus (abdominal cramping, swelling, nausea, vomiting, constipation, and the inability to eat and digest a normal diet). By May 1st, the MDL now includes 87 claims related to serious digestive side effects caused by this drug. If you are considering this lawsuit, the legal team at Lawsuit Legal News can answer all your questions.

April 24, 2024 - Defendants Offically Counter Plaintiffs' Claim That Ozempic Can Cause Stomach Paralysis

The defendants in the MDL (Novo Nordisk and Eli Lilly) have officially challenged the plaintiffs' claim regarding the link between GLP-1RA medicines and stomach paralysis, aggressive marketing, and failure to change the label.

One of their main points was that plaintiffs could not prove causation at future trials. The plaintiffs claim that these drugs increase the risk of severe gastrointestinal issues, such as gastroparesis, ileus, and bowel obstruction. However, the manufacturers argue that there is no significant evidence linking the drugs to these conditions because diabetes itself can cause these same issues, which many plaintiffs already have.

The plaintiffs have also challenged the fact that Ozempic and other similar drugs have aggressively marketed and spent a ton of money on advertising despite their drugs not being FDA-approved specifically for weight loss. The manufacturers addressed their aggressive marketing strategies.

They contend that the medical community is well aware of the gastrointestinal side effects associated with these drugs and, therefore, could have warned their patients. This case will explore whether the drug companies' marketing practices were misleading about the severity of the potential side effects and the long-term use of the drugs.

April 2, 2024 - Ozempic Maker Spends $11 Million to Market Drug For Weight Loss

The LLN team has learned that Novo Nordisk budgeted 11 million dollars to pay for doctors' travel and dining expenses as a marketing strategy to encourage them to prescribe Ozempic and other similar drugs for weight loss purposes. The money was used to pay 12,000 physicians for 457,000 meals and trips to places including Honolulu, Paris, London, and Orlando.

Critics have noted, and our legal professionals agree, that this large sum of money could have been better spent on research to determine the extent of the drug's serious side effects and long-term concerns, including stomach paralysis and other digestive problems. This information will make it difficult for Novo Nordisk to argue it doesn't have the funds to pay settlement amounts or verdicts awarded to the patients who were injured by this medication.

March 29, 2024 - Judge Pratter Stresses Efficiency During First Hearing in Ozempic Lawsuit MDL

Judge Pratter of the Eastern District of Pennsylvania stressed that she wants to see little in the way of bickering and good communication between all parties to the newly formed Ozempic multi district litigation (MDL). Further, she harped on efficiency and warned the lawyers from requesting delays and new dates. 

There are presently 72 lawsuits consolidated in the United States District Court for the Eastern District of Pennsylvania. A number of plaintiff lawyers are predicting the Ozempic lawsuit MDL could eventually house over 20,000 cases of individuals who were prescribed Ozempic or other GLP-1 receptor agonists (glucagon-like peptide-1) such as Mounjaro, Wegovy, and Trulicity. The lawsuits contain a common allegation that the use of the GLP-1 receptor agonists raises the risk of severe stomach paralysis. 

Semaglutide is the active ingredient in Ozempic and Wegovy while tirzepatide is the active ingredient of Mounjaro. Unfortunately, these ingredients are designed to slow down digestion. In some cases, it can almost completely shut down the process. We have a number of clients who allege intestinal blockages, gastrointestinal burning along with stomach paralysis. More adverse event reports were associated with the semaglutide drugs.

Many of these individuals report visiting the emergency room and a few required surgical intervention. These dangerous drugs completely slow down the digestion process. There is a new body of research linking Ozempic (semaglutide) to gastrointestinal adverse events. In turn, plaintiffs allege they were not adequately warned of any risks associated with using diabetes medications off label for weight loss.

March 1, 2024 - Ozempic Multidistrict Litigation Officially Begins With First Scheduled Court Date

March 14, 2024, is the date for the first status conference in the federal Multidistrict Litigation (MDL). US District Judge Gene E.K. Pratter was assigned to preside over the many cases involved in the MDL. We should learn more about how these lawsuits will proceed in a few weeks.

A recent study reported in the BMJ confirmed that GLP-1 receptor agonist drugs provide many benefits for diabetes patients. However, these patients are also facing a greater chance of gastrointestinal problems, including vomiting, nausea, and complications while digesting food. Higher doses of the medications tend to cause more side effects, so dosage is also an important factor regarding these problems.

Another new study posted by Frontiers Journals used the FDA Adverse Event Reporting System to conclude these weight loss drugs are also associated with psychiatric adverse events in patients.

February 6, 2024 - Multi-District Litigation (MDL) is Created; Ozempic and All Similar Medications Included

The MDL Panel agreed with the majority of the injured plaintiffs that all federal lawsuits involving Ozempic and similar drugs should be consolidated into an MDL. This litigation will now be assigned to Judge Gene Platter of the United States District Court of the Eastern District of Pennsylvania, located in Philadelphia, PA. 

Although defendants Novo Nordisk and Eli Lilly requested different jurisdictions in California or North Carolina, the panel chose Pennsylvania since many pending lawsuits were already filed in that jurisdiction. Also, the Eastern District of Pennsylvania is close to Novo Nordisk's New Jersey headquarters.

Novo Nordisk will now face a huge risk that may dramatically impact its stock price. Ozempic is already an industry staple, but now Wegovy (both Ozempic and Wegovy are semaglutide medications) is exploding in popularity. Wegovy is essentially a very similar formula to Ozempic but is marketed solely as a weight-loss medication. 

The team at Lawsuit Legal News predicts the MDL will draw thousands of claims from people who suffer severe gastrointestinal issues after using GLP-1 receptor agonist medications, including Ozempic, Wegovy, Mounjaro, Rybelsus, and Trulicity. 

We expect the main legal theory will be a failure to warn users of the potentially serious medical complications these drugs can cause. We are pleased the Panel kept all of the drug makers in the MDL as potential defendants. At the end of the day, plaintiffs must prove the drug manufacturers failed to adequately warn patients of known risks such as ileus or gastroparesis. All that the warning label references is that the use of Ozempic delays gastric emptying. The warning label makes no other mention of gastric problems.

January 31, 2024 - Defense Lawyers and One Plaintiff Lawyer Argue  MDL Should be Limited to Only Novo Nordisk (Ozempic & Wegovy)

The defense lawyers and a single plaintiff's lawyer argued to the JPML (Judicial Panel of Multidistrict Litigation) panel last week that the MDL should be limited only to Novo Nordisk. They argued there's a stronger link between Semaglutide (the main ingredient in Ozempic) and gastroparesis and other potential side effects, including ileus, bowel obstruction, intestinal obstructions, and intestinal blockage, than other similar drugs like Mounjaro, which contain tirzepatide.

If the defense has its way, the only defendant pharmaceutical company would be Novo Nordisk, and Eli Lilly would be out of the lawsuit.  Drug manufacturers of other diabetes medications utilized off-label for weight loss could face a separate MDL.  

Plaintiff lawyers have requested that Ozempic lawsuits be consolidated in the Western District of Louisiana or any Federal District in Pennsylvania.  The defendants have sought centralization in North Carolina or California.   It should be interesting to see whether the forthcoming Ozempic MDL is only limited to the use of semaglutide medication.

Jan 25, 2024 - JPML Meets Today to Decide If All Federal Cases Will Be Combined to Resolve the Litigation Faster

The Judicial Panel on Multidistrict Litigation (JPML) is having its session to discuss combining Ozempic lawsuits into a multidistrict litigation (MDL). The hearing is taking place in Santa Barbara, California. When the news will come out, we are not sure. But we will let you know ASAP.

Jan 24, 2024 - Counterfeit Ozempic Causes Concern as it Floods the US Market, FDA

Ozempic, the diabetic medication that was discovered to help patients lose a ton of weight in a small amount of time, is facing a double whammy today as its litigation nightmare over serious side effects collides with new findings that fake versions of the drug are "flooding US supply chain". I think it's safe to say that this once-touted 'miracle drug' is getting a new reputation when compared to its moment in the sun just a year or so ago.

As if concerns over common side effects including stomach paralysis and gallstones weren't worse enough, now people have to worry that the Ozempic they're taking is counterfeit.

Three cases of severe low blood sugar linked to the fake Ozempic have been reported so far. As of now, what we know is that the fake medication contained insulin instead of semaglutide, which is the correct drug for Ozempic.

This new issue creates concerns beyond the existing concerns that are already present for genuine Ozempic and may fuel legal arguments about Novo Nordisk's transparency.

The FDA has stepped up its fight against counterfeit Ozempic, seizing shipments and working with international partners to disrupt the supply chain. While this crackdown aims to protect consumers from the dangerous fake Ozempic, it also shows that the medication's popularity is making it more appealing to drug counterfeiters.

In fact, the medication has become so popular, that being able to find it in places like Beverly Hills has become fodder for funny TikToks.

These original injury and death claims and counterfeit concerns create a complex mess where safety and marketing ethics collide.

As Ozempic's popularity continues, it will be up to regulators and manufacturers to help keep patients safe.

January 8, 2024 - Motion to Consolidate Stomach Paralysis Lawsuits to be Heard January 25, 2024.

The Ozempic class action lawsuit may soon evolve into multidistrict litigation.  On January 25, 2024, the motion to form an MDL will be presented to the Joint Panel on Multidistrict Litigation in Santa Barbara, California. The common goal is to consolidate all stomach paralysis lawsuits that have been filed in Federal District Courts throughout the United States before Judge James Cain in the Western District of Louisiana due to common questions of fact and for the purpose of consolidated discovery.  

Back in November, the Food and Drug Administration (FDA) updated the Ozempic warning label to reference reports stating adverse events of blocked intestines.  The FDA is now acknowledging numerous reports of a condition called ileus, which is essentially blocked intestines.  The FDA has also received reports of gastroparesis (paralyzed stomach). This occurs when the muscles in the stomach are weakened and delay the digestion and movement of food.  As a result, food sits in the stomach for far too long, leading to a host of other health issues.  

Plaintiffs in Ozempic lawsuits claim Novo Nordisk failed to warn consumers about the potential risk of medical issues related to this prescription medication.  Failure to warn claims based on inadequate warnings will center on when the manufacturer of Ozempic (Novo Nordisk) was first made aware that the use of this diabetic medication (used off-label as an obesity drug) might be causally related to stomach paralysis.  Ozempic belongs to a class of drugs known as GLP-1 Agonist Medications.  Other GLP-1 drugs include Wegovy (also manufactured by Novo Nordisk and Mounjaro (made by Eli Lilly). 

We are presently investigating all drugs that fall into the same class as GLP-1 agonists.

December 8, 2023 - Motion to Dismiss Lawsuit Filed by Novo Nordisk is Denied 

Federal Judge James Cain, Jr., denied Novo Nordisk's motion to dismiss, stating the plaintiff had provided enough evidence to show the manufacturer of Ozempic failed to warn physicians about the risk of gastroparesis.  Jaclyn Bjorklund (the plaintiff) will continue forward in her failure to warn lawsuit against Novo Nordisk.  There are simply too many adverse reactions being reported by patients for Judge Cain to dismiss this Ozempic stomach paralysis lawsuit.

November 13, 2023 - Weight Loss Drugs Linked to Risk of Delayed Gastric Emptying & Gastrointestinal Issues

The risk of stomach paralysis by those using a semaglutide drug like Ozempic or Wegovy is too significant to ignore, according to a new study published in the Journal of the American Medical Association. The authors used a cohort study of GLP-1 agonists and measured individual users against those utilizing regular weight loss drugs.  The subjects using GLP-1 agonists such as Ozempic and Wegovy had a substantially increased risk of pancreatitis and other severe side effects. Doctors would be mindful in prescribing GLP-1 medications for weight loss.  

October 1, 2023 - Warning Label for Ozempic is Updated per FDA

 Warning Label for Ozempic

The FDA is now acknowledging the numerous complaints of intestinal blockage.  However, the FDA has not changed the warning label to include gastroparesis or stomach paralysis.  While similar, gastroparesis is not the same as ileus, the medical term for intestinal blockage. Gastroparesis occurs when food can not reach the small intestine without blockage in the intestines.  

Ozempic's warning label already references the drug causes delay of gastric emptying (delay of stomach emptying).  The FDA says it will continue monitoring reports of gastroparesis and will act accordingly.  At the same time, the FDA did not comment on complaints or a potential warning of other gastrointestinal events such as severe vomiting or excessive vomiting, cyclic vomiting syndrome, digestive issues, or other severe stomach issues.   

Meanwhile, physicians concerned with patient safety and reports of gastrointestinal issues should consider other options when considering weight loss drugs. Based on adverse event reports, the risk of gastroparesis should not be ignored.  We also hope that physicians prescribing Ozempic off-label for weight loss should consider whether the patient has type 2 diabetes.  

A few more lawsuits have been filed nationally. We are hearing that a proposed class action lawsuit is on the horizon. If you are thinking of filing a lawsuit for injuries after taking Ozempic, we expect this litigation to be consolidated into multidistrict litigation (MDL) in the coming months. 

Can you request compensation for Ozempic injuries?

What is Ozempic, and Why Is It Controversial?

Why Is It Controversial

Ozempic is an FDA-approved diabetes drug produced by Novo Nordisk. The drug has also been used for weight loss. Ozempic is a GLP-1 Receptor Agonist Analog-Type drug used to control high blood sugar in type 2 diabetics. 

The drug does this by replicating the effects of incretin glucagon-like peptide-1 (GLP-1) and helping to regulate blood sugar by stopping excess sugar production in the liver and signaling the pancreas to generate more insulin, which is a primary issue for type 2 diabetics. Ozempic comes in an injector pen and is administered once a week.

While Ozempic has shown some positive results for many, it still has caused many patients to develop unprecedented health conditions that they were not aware the drug had a risk of causing. 

Ozempic slows down the digestion rate, leading to a loss of appetite based on feeling full for longer. However, there have been far too many adverse event reports, including gastrointestinal injuries such as ileus, bowel obstruction, intestinal obstruction, intestinal blockage, and gastroparesis.

Ozempic and Gallstones

The new lawsuits against Ozempic over it causing gastroparesis come after many lawsuits have already been filed over Ozempic’s connection to gallstones and other gallbladder-related illnesses. Several people have come forward with diagnoses of cholelithiasis, also known as gallstones, which they claim are connected to their use of Ozempic. Studies have found that 1 in 6 patients taking Ozempic will develop gallstones.

Gallstones occur when the gallbladder is unable to properly process bile, which leads to the creation of stones made up of accumulated bile materials. These gallstones can pass through the body naturally in cases when they are small and occasional but can be painful when they are large or numerous, such as in the cases of plaintiffs suing Ozempic manufacturers. 

Studies Connecting Ozempic to Gallstones

Researchers have connected the use of Ozempic to an increased risk of gallstones. A 2017 study found through data collected from 113 clinical trials that GLP-1 drugs taken by patients with type 2 diabetes increased the risk of cholelithiasis.

The same researchers would go on to support these findings by conducting another study in 2020 using an updated meta-analysis. 

Another study conducted by Chinese researchers used data from 76 clinical trials to determine that there was a connection between patients who used GLP-1 drugs and the diagnosis of gallbladder issues that included gallstones.

Ozempic is a drug that many patients put their trust in and came out worse for wear after experiencing severe health conditions such as gastroparesis and cholelithiasis. It is not unusual for drugs to have negative side effects, but it is the manufacturer’s duty to inform consumers of risks, which Novo Nordisk failed to do with regard to gallstones and gastroparesis. 

The damage inflicted by these health conditions, in many cases, may not be life-threatening but can still cause significant disruption to someone’s life, both financially and personally. Economic damages such as medical expenses and lost wages from time spent recovering, as well as non-economic damages such as mental anguish or pain and suffering, are compensable through a lawsuit settlement. Some other common damages claimed in these lawsuits include:

  • Medical bills
    • Lab tests
    • Imaging
    • Medication
    • Surgery
    • Hospital stays
  • Job-related losses
    • Lost wages
    • Missed promotions
  • Mental anguish

Learn how much you can recover

Potential Long-Term Effects of Ozempic

GLP-1 agonists like semaglutide are designed for extended and, in some cases, lifelong use as weight-management medications. However, there remains limited knowledge about potential long-term adverse effects, especially among individuals using these drugs for obesity, according to a recent study published in the JAMA Medical News and Perspectives.

One potential concern is medullary thyroid cancer, as indicated by rodent studies. Yet, since cancer is a latent disease, it will take many years to accumulate substantial data on its impact on individuals.

It's important to note that a personal or family history of medullary thyroid cancer is considered a contraindication for Dulaglutide, Liraglutide, Semaglutide, and the newly approved Tirzepatide. Tirzepatide, unlike other GLP-1 agonists, mimics two gut hormones, offering a distinct approach.

As Kasia Lipska, MD, an associate professor of medicine in endocrinology at the Yale School of Medicine, points out, people are often prescribed these medications for potentially extended durations, and our understanding of their effects may evolve over time. Nevertheless, she anticipates these newly recognized adverse effects will likely remain infrequent.

Etminan's research focus is now shifting from stomach-related concerns to potential ocular adverse effects associated with GLP-1 agonists, particularly among individuals with obesity. While some studies have hinted at an increased risk of retinopathy in individuals with type 2 diabetes using Semaglutide, his 2018 study did not find this association.

This emphasizes the need for ongoing research to better comprehend the long-term implications of Ozempic use, including potential health risks. If you have concerns regarding Ozempic-related effects, it is advisable to consult with experienced legal professionals for guidance.

How an Ozempic Lawyer Can Help

After receiving a diagnosis of gastroparesis of cholelithiasis after using Ozempic, consumers harmed by this product should consider hiring a product liability lawyer. Getting expert legal representation is integral if you are considering filing an Ozempic stomach paralysis lawsuit since knowledge of your rights and the legal process can mean the difference between a fair settlement and walking away from a lawsuit with nothing. 

An experienced product liability lawyer will advocate on your behalf and assist in the negotiation of a settlement, gathering evidence, calculating your damages, and more. Ultimately, lend professional skills and resources to plaintiffs still dealing with Ozempic-related injuries and manage your case so you can focus on recovery. 

Contact an Experienced Product Liability Lawyer About Your Ozempic Lawsuit

Lawsuit Lawyer
Lawsuit Lawyer, Matt Dolman

If you or a loved one have suffered severe symptoms of gallstones or another illness you believe to be associated with Ozempic use, then consider contacting a product liability lawyer as soon as possible about your case.

Contacting an Ozempic lawyer can provide you with valuable information regarding the viability of a potential lawsuit and jumpstart the process of attaining fair compensation for your severe gastrointestinal issues. Reach out to the skilled lawyers associated with Lawsuit Legal News for a free consultation to see if they can help you seek compensation.

Our experienced Ozempic lawyers, who also handle other Semaglutide drugs such as Wegovy and Mounjaro, can evaluate your case to determine whether or not you may be eligible to seek financial compensation, the value of any damages you may have and what legal options are available to you. 

Our law firm can immediately file a lawsuit to preserve your potential claim. Call us today at 866-535-9515 or fill out our simple online form to schedule a free consultation and free case review with our Ozempic lawyers, Dolman Law Group. The Ozempic attorneys at Dolman Law Group are presently investigating hundreds of potential Ozempic gastroparesis lawsuits nationwide, and they can help you too! 

Don't wait any longer. Contact the dedicated legal team at Lawsuit Legal News below.

Contact the dedicated legal team at Lawsuit Legal News

Latest News